Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis

Published:2020-10-07 Issue:6 Volume:53 Page:1139-1147
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Zhang Siliang,Guo Jing,Xie Shuqin,Chen Jianwei,Yu Shenrun,Yu Yuan

Funder

Natural Science Foundation of Yongchuan District

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

https://link.springer.com/content/pdf/10.1007/s11255-020-02671-z.pdf

Reference21 articles.

1. Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD (2019) Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfz192

2. Gafter-Gvili A, Schechter A, Rozen-Zvi B (2019) Iron deficiency anemia in chronic kidney disease. Acta Haematol 142:44–50. https://doi.org/10.1159/000496492

3. Spoto B, Kakkar R, Lo L, Devalaraja M, Pizzini P, Torino C, Zoccali C (2019) Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and in CKD patients: a two cohorts study. J Clin Med 8:523. https://doi.org/10.3390/jcm8040523

4. Befani C, Liakos P (2018) The role of hypoxia-inducible factor-2 alpha in angiogenesis. J Cell Physiol 233:9087–9098. https://doi.org/10.1002/jcp.26805

5. Dhillon S (2019) Roxadustat: first global approval. Drugs 79:563–572. https://doi.org/10.1007/s40265-019-01077-1

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Care of Adults with Advanced Chronic Kidney Disease;Journal of Clinical Medicine;2024-07-26

2. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations;Clinical Kidney Journal;2023-12-07

3. Multimodal Imaging Reveals that Sustained Inhibition of HIF-Prolyl Hydroxylases Induces Opposing Effects on Right and Left Ventricular Function in Healthy Rats;Molecular Imaging and Biology;2023-12-06

4. Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses;Frontiers in Pharmacology;2023-11-30

5. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis;Frontiers in Endocrinology;2023-03-16